ASX Healthcare Divergence
CSL Reports Statutory Loss While Pro Medicus Achieves Record Growth
Anonymous
Key Points
1
CSL incurred approximately USD 799 million in pre-tax restructuring expenses during FY26 as part of its business reset.
2
CSL’s underlying net profit after tax was approximately USD 2.84 billion, highlighting the substantial difference between its underlying performance and its USD 2.58 billion statutory loss.
3
Pro Medicus signed 10 new agreements during FY26 with a combined minimum contract value of approximately AUD 407 million, providing additional contracted revenue beyond its reported annual results.
4
Pro Medicus’s Visage platform is cloud-based radiology viewing and workflow technology used by large healthcare systems, particularly in the United States; its commercial model includes multi-year contracts and transaction-based licensing tied to customer imaging volumes.
Three major ASX healthcare companies delivered sharply different FY26 results, revealing winners and losers in the sector's varied markets. Kalkine reports that CSL posted USD 15.8 billion in revenue but a USD 2.58 billion statutory loss after USD 7.1 billion in impairment charges and restructuring costs. Pro Medicus, by contrast, surged 22.9% in revenue to AUD 261.7 million with a 74.9% underlying profit margin and remained debt-free. Telix continues advancing its radiopharmaceutical pipeline as execution and regulatory milestones loom in FY27.
The divergent results underscore the healthcare sector's complexity — from CSL's restructuring pain to Pro Medicus's cloud-based software dominance to Telix's pipeline risks. Yahoo Finance notes the broader biotech sector expects recovery in 2026 backed by clinical wins and M&A activity, yet individual company outcomes depend heavily on execution.
CSL's Massive Restructuring Dwarfs Underlying Profit
CSL's statutory loss masks a very different operating reality. The company's underlying net profit after tax reached approximately USD 2.84 billion — making the USD 2.58 billion statutory loss almost entirely driven by charges. Kalkine reports CSL incurred roughly USD 799 million in pre-tax restructuring expenses during FY26 as part of a major business reset. Management expects FY27 revenue to remain broadly stable, with underlying net profit growing about 5%.
The gap between statutory and underlying results is striking: USD 2.84 billion in underlying profit versus a USD 2.58 billion loss on paper. This dramatic swing reflects one-time charges and impairment costs rather than deteriorating core operations, suggesting the company's plasma therapy business continues generating strong cash despite restructuring headwinds.
Pro Medicus Powers Ahead With Cloud Software Dominance
Pro Medicus delivered the sector's standout performance, with revenue growth of 22.9% to AUD 261.7 million and a towering 74.9% underlying EBIT margin. The company remains debt-free with AUD 252.3 million in cash and financial assets. Kalkine reports the company signed 10 new agreements during FY26 worth a combined AUD 407 million in minimum contract value, building a fortress of future revenue.
The company's Visage cloud-based radiology viewing platform serves large US healthcare systems through multi-year contracts and transaction-based licensing tied to imaging volumes. Kalkine notes these long-term contracts provide stability as new customer implementations come online, positioning Pro Medicus for sustained growth in the large US healthcare software market.
Telix Races Toward Key Commercial and Regulatory Milestones
Telix's FY26 results reflect a company firmly in growth mode, advancing diagnostic and therapeutic radiopharmaceutical programs through development and into commercial deployment. Kalkine reports the company is building its commercial portfolio while managing multiple pipeline programs, with execution and regulatory approvals critical to FY27 momentum.
Radiopharmaceuticals remain an emerging market segment, and Telix's success hinges on timely regulatory wins and customer demand for its products. Unlike Pro Medicus's established cloud software market or CSL's legacy plasma business, Telix carries higher execution risk — but also higher potential upside if regulatory milestones clear and adoption accelerates.
Healthcare Sector Recovery Ahead as M&A Wave Builds
Yahoo Finance reports the broader drug and biotechnology sector is expected to see recovery in 2026, underpinned by encouraging clinical and regulatory developments, improving outlooks, and rising M&A activity. The diverging FY26 results from CSL, Pro Medicus and Telix reflect this uneven recovery — some companies are already thriving while others like CSL are cutting costs and restructuring.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
18
Reach
34
A
AnonymousAuthor
